Low incidence of genetic alterations of the p16CDKN2a in clear cell chondrosarcoma

Y K Park1, C H Cho, S G Chi

  • 1Department of Pathology, College of Medicine, Kyung Hee University Hospital, Seoul 130-702, Korea. ykpark@khmc.or.kr

Insights

Genetic alterations of the p16CDKN2a tumor suppressor gene are rare in clear cell chondrosarcoma. This study found no significant involvement of p16CDKN2a gene alterations in the development of this specific cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Cyclin-dependent kinase inhibitors (CDKIs), including p16CDKN2a, are crucial tumor suppressor genes.
  • Mutational inactivation of CDKIs is implicated in various human cancers.
  • The role of CDKI abnormalities in clear cell chondrosarcoma remains largely unexplored.

Purpose of the Study:

  • To investigate the frequency and significance of p16CDKN2a gene alterations in clear cell chondrosarcoma.
  • To determine if p16CDKN2a gene abnormalities contribute to the development of clear cell chondrosarcoma.

Main Methods:

  • Quantitative DNA/PCR was used to assess p16CDKN2a gene amplification levels.
  • PCR-SSCP (Single-Strand Conformation Polymorphism) analysis was employed to detect sequence alterations.
  • 38 clear cell chondrosarcoma tissue specimens were analyzed.

Main Results:

  • Abnormally low p16CDKN2a amplification was detected in only 2 out of 38 specimens (5.2%), suggesting low-frequency allelic deletion.
  • No altered SSCP patterns were observed across the entire coding region of the p16CDKN2a gene in any specimen.
  • The study indicates a very low incidence of genetic alterations involving the p16CDKN2a gene in clear cell chondrosarcoma.

Conclusions:

  • Alterations in the p16CDKN2a gene are infrequent in clear cell chondrosarcoma.
  • The p16CDKN2a gene is not significantly involved in the pathogenesis of clear cell chondrosarcoma.
  • Further research may explore other genetic factors contributing to clear cell chondrosarcoma development.